Skip to main content
Fig. 2 | BMC Nephrology

Fig. 2

From: Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4–5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trial

Fig. 2

Total body water analysis by bioimpedance vectors. The bumetanide plus placebo group is shown in blue (control group), and the bumetanide plus chlorthalidone group is shown in red (intervention group). A There was decreased volume overload in liters of TBW on Day 7 [intervention: -2.5 (95% CI, -3.6 to -1.5) vs. control: -0.59 (95% CI, -1.8 to 0.67), p = 0.003] and Day 30 [intervention: -5.3 (95% CI, -8.6 to -1.95) vs. control: -0.07 (95% CI, -1.02 to 0.87) p = 0.016]. B There was a decrease in ECW on Day 7 [intervention: -1.58 (95% CI, -1.95 to -1.2) vs. control: -0.43 (95% CI, -1.2 to 0.31) p < 0.001] and Day 30 [intervention: -3.05 (95% CI, -4.47 to –1.62) vs. control: -0.15 (95% CI, -0.8 to -0.5), p < 0.000]. C There was a reduction in the ECW/TBW ratio on Day 7 [intervention: -1.29 (95% CI, -2.32 to -0.25) vs. control: -0.72 (95% CI, -1.64 to 0.20), p = 0.384] and Day 30 [intervention: -4.38 (95% CI, -7.8 to -0.92) vs. control: -0.24 (95% CI, -1 to 0.52), p = 0.018]

Back to article page